Physicians' Academy for Cardiovascular Education

HF & Diabetes: SGLT2 inhibition a paradigm shift?

10' education - Aug. 29, 2016 - ESC 2016, Rome, Italy - John McMurray, MD University of Glasgow United Kingdom - Recorded at PACE-CME symposium held during ESC 2016 in Rome

This lecture was part of a CME accredited symposium: SGLT2 Inhibition, Diabetes and CVD: Where does this fit in CV risk management? held at ESC 2016 in Rome

Video navigation menu

  • Multiple hypotheses on prevention of heart failure and reduction of mortality by SGLT-2 inhibitors 01:31
  • Direct or indirect effect on myocardium by SGLT-2 inhibitors 02:55
  • Lack of effect on myocardial infarction and absence of evidence for antiarrhythmic effect by SGLT-2 inhibitors 04:10
  • Blood pressure-lowering effect of SGLT-2 inhibitors 05:13
  • Renal effect of SGLT-2 inhibitors 11:40
  • Heart failure and mortality 12:54
  • Can we treat established heart failure with SGLT-2 inhibitors? 16:36

Educational information

Educational objectives of this symposium were to:

CME accreditation

This symposium was accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).


Professor John McMurray: Professor of Medical Cardiology & Deputy - Director Institute of Cardiovascular & Medical Sciences - University of Glasgow, United Kingdom


Supported by an unrestricted educational grant from Boehringer Ingelheim/Lilly.

Also see lecture - Challenging cardiovascular risk in diabetes: ready for a new approach by Prof. John Deanfield, MD, UCL, London Also see lecture - Overview of SGLT-2 inhibitors in T2DM management: current position & future promise by prof Silvio Inzucchi, MD, Yale Diabetes Center, New Haven, USA

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: